NuGenerex Immuno-oncology, Inc. (NGIO)

NuGenerex Immuno-oncology will go public soon, but the exact IPO date is still unknown.
Stock Price: $8.50 - $9.50
Current IPO price range
Chart not available yet
Data will show when the stock starts trading.
Market Cap 952.70M
Revenue (ttm) n/a
Net Income (ttm) -4.63M
Shares Out 105.86M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About NGIO

NuGenerex Immuno-oncology is focused on the regulation of the immune system to treat cancer and infectious diseases. To that end, we are developing immunotherapeutic products and vaccines based on our proprietary, patented platform technology, Ii-Key. With the Ii-Key vaccine technology, we are able to activate the immune system against target molecules, whether those targets are tumor associated antigens (TAAs) in cancer cells, or viral or bacterial proteins in infectious disease pathogens. Through our 20+ year history of research and developme... [Read more...]

Industry Pharmaceutical Preparations
Founded 1993
CEO Joseph Moscato
Employees 6
Stock Exchange NASDAQ
Ticker Symbol NGIO
Full Company Profile

Financial Performance

Financial Statements


NuGenerex Immuno-oncology IPO Registration Document (S-1)

NuGenerex Immuno-oncology, Inc. has filed to go public with an IPO on the NASDAQ.